The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

A nasal spray of oxytocin significantly reduced acute ... there is growing interest in using oxytocin as a treatment for various mental health conditions. Research suggests that elevated levels ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment ... full remission from their symptoms after using one antidepressant medication, and 50% ...